CD39 Double Nickase Plasmid (h): sc-402644-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD39 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD39 Double Nickase Plasmid (h) and CD39 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting ENTPD1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD39 Antibody (BU61): sc-65262
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD39 Double Nickase Plasmid (h) | sc-402644-NIC | 20 µg | $410.00 | |||
CD39 Double Nickase Plasmid (h2) | sc-402644-NIC-2 | 20 µg | $410.00 |
Human ENTPD1 encodes CD39 (ectonucleoside triphosphate diphosphohydrolase 1), a cell-surface ectoenzyme that hydrolyzes extracellular ATP and ADP to AMP, thereby shaping purinergic signaling and nucleotide-driven inflammatory cues. By controlling substrate availability for CD73-mediated adenosine production, CD39 helps regulate leukocyte activation, endothelial homeostasis, platelet reactivity, and tissue protection during stress. ENTPD1 activity intersects with P2 receptor signaling, hypoxia-associated programs, and immunometabolic pathways that influence cytokine release and barrier function. Dysregulated CD39 expression or activity has been linked to tumor immune evasion, chronic inflammation, vascular dysfunction, and thrombosis-related phenotypes in experimental systems.
CD39 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the ENTPD1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within ENTPD1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt ENTPD1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of ENTPD1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.